Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
CytoDyn’s monoclonal antibody PRO 140 injected once a week suppressed HIV in some people living with the virus for well over a year.
Celebrating 20 years of effective HIV treatment
Here’s a timeline of the highlights.
A new entry inhibitor (EI) is in the works.
Long-awaited results from a Phase II study of ibalizumab, an antibody-based therapy in early stage development for several years
Tobira Therapeutics is recruiting for a Phase IIb study of its CCR5/CCR2 entry inhibitor cenicriviroc (TBR-652). It is hoped that cenicriviroc...
People taking older anti-seizure medications that are broken down by the same liver enzyme (CYP3A4) as many common antiretroviral (ARV) drugs...
People who failed treatment on the entry inhibitor Selzentry had good long-term health outcomes after switching their antiretroviral (ARV) reg...
An experimental HIV entry inhibitor might be particularly well suited for use as a preventive microbicide—due to the area of the virus i...
Merck announced July 14 that it is abandoning development of vicriviroc, the company’s CCR5-blocking HIV entry inhibitor candidate. In a state...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.